The UV research groups (GIUV) are regulated in the 1st chapter of the Regulation ACGUV48/2013, which explains the procedure for creating new research structures. They are basic research and organizational structures that result from the voluntary association of researchers that share objectives, facilities, resources and common lines of research. These researchers are also committed to the consolidation and stability of their activity, work in groups and the capability to achieve a sustainable funding.
The research groups included in the previously mentioned Regulation are registered in the Register of Research Structures of the Universitat de València (REIUV), managed by the Office of the Vice-principal for Research. The basic information of these organisms can be found in this website.
Participants
Data related to research groups featured in various information dissemination channels shall not, under any circumstances, imply a statement or commitment regarding the employment or academic affiliation of individuals associated with the Universitat de València. Their inclusion is solely the responsibility of the group directors. Updates will be made upon request from interested parties.
- Registered groups in the Register of Research Structures of the Universitat de València - (REIUV)
Reference of the Group:
Description of research activity: The Research Group on Molecular Therapies is made up of basic and clinical researchers from the Universitat de València, the La Fe University Hospital, the University Clinical Hospital of Valencia, the University Hospital of the Ribera, the National Cancer Research Centre and the Prince Felipe Research Centre. The multidisciplinary composition of this group, which includes experts in molecular biology, bioinformatics and computational biology, medical oncology, surgery, pathology and new high-throughput technologies (genomics, transcriptomics, proteomics and metabolomics), allows the molecular complexity inherent to human diseases and the search for new therapies from an integrative and translational perspective. This approach is being applied in the different lines of research developed by the group, such as the identification of new biomarkers and molecular targets for the treatment of lung cancer, the physiopathology of pulmonary fibrosis, or the prevention and therapy of hypoxic-ischaemic neuropathies.
Web:
Scientific-technical goals: - Nuevas terapias dirigidas contra dianas moleculares en el adenocarcinoma pulmonar
- Nuevas terapias dirigidas contra la fibrosis pulmonar
- Nuevas terapias basadas en polifenoles naturales
Research lines: - New targeted therapies in lung cancer.Functional genomics of lung cancer. Identification of new markers and molecular targets for the treatment of lung cancer using omics technologies (transcriptomics, proteomics, metabolomics). Study of the mechanisms of innate and acquired resistance to tyrosine kinase inhibitors based on the epithelial-mesenchymal transition (EMT) and the cancer stem cell (CSC) phenotype. Regulation of tumour metabolism by oncogenes and suppressor genes in lung cancer.
- New targeted therapies in pulmonary fibrosis.Identification of new markers and molecular targets for the treatment of pulmonary fibrosis. Identification of molecular determinants of fibroblast-myofibroblast transition using omics technologies. Role of inflammation and stroma in the tumour microenvironment and lung cancer progression.
- New therapies based on natural polyphenols.Identification of new markers associated with oxidative metabolism by mass spectrometry. Study of pathologies associated with oxidative stress and tissue hypoxia. Cellular and molecular mechanisms of the prevention of tissue damage in hypoxic-ischaemic neuropathies by means of natural and synthetic polyphenols.
Group members:
| Name |
Nature of participation |
Entity |
Description |
| JULIAN CARRETERO ASUNCION | Director | Universitat de València | |
| Research team |
| MIGUEL ANGEL ASENSI MIRALLES | Member | Universitat de València | |
| JAVIER PEREDA CERVERA | Member | Universitat de València | |
| JOSE MARCELO GALBIS CARAVAJAL | Collaborator | Hospital de la Ribera | researcher |
| FATIMA AL-SHAHROUR NUÑEZ | Collaborator | Fundacion Centro Nacional de Investigaciones Oncologicas Carlos Iii | researcher |
| ROSA FARRAS RIVERA | Collaborator | Fundación Centro de Investigación Príncipe Felipe | researcher |
| AGUSTIN LAHOZ RODRIGUEZ | Collaborator | null | postdoctoral researcher |
CNAE:
Associated structure:
Keywords: - Cáncer, pulmón, terapias dirigidas, tecnologías ómicas, EMT, CSC
- Fibrosis, miofibroblasto, cáncer, estroma, inflamación
- Metabolismo, Hipoxia, polifenoles, estrés oxidativo
